Report Description Table of Contents Leukapheresis Becomes the Starting Line for Cell Therapy Scale – (Updated On: 29th-Sep-2026) The Global Leukapheresis Market was valued at USD 247.80 million in 2025 and is projected to reach USD 444.63 million by 2032, expanding at a CAGR of 8.71% during 2026–2032, according to Strategic Market Leukapheresis is primarily used for rapid reduction of extremely high white blood cell counts in hematological disorders such as leukemia, helping manage complications associated with hyperleukocytosis and leukostasis. The market is primarily driven by two major application areas: therapeutic leukapheresis for hematological emergencies and leukocyte collection for advanced cellular therapies, including CAR-T therapy and hematopoietic stem cell transplantation. Therapeutic leukapheresis remains an important intervention for patients with acute leukemias and hyperleukocytosis, where rapid reduction of circulating white blood cell levels is required to manage complications such as leukostasis. Global leukemia incidence exceeds 500,000 new cases annually, with acute myeloid leukemia (AML) representing one of the key patient groups associated with high white blood cell counts requiring urgent hematological management. The largest commercial opportunity for leukapheresis is emerging from the rapid expansion of cell and gene therapy manufacturing workflows. Autologous CAR-T therapies require patient-specific leukapheresis collection as the initial step for harvesting T cells before genetic modification and reinfusion. With more than 20,000 patients receiving commercial CAR-T therapies globally since initial approvals, every treatment cycle generates demand for leukapheresis procedures, disposable collection systems, and cell processing infrastructure. Hematopoietic stem cell transplantation ecosystem also contributes significant demand through peripheral blood stem cell collection procedures. More than 150,000 hematopoietic stem cell transplantation procedures are performed annually worldwide, supported by increasing use of peripheral blood-derived stem cells compared with traditional bone marrow harvesting approaches. Key industry participants are strengthening their presence through technology development and partnerships across blood processing and cell therapy applications. Terumo Blood and Cell Technologies continues to develop automated apheresis platforms supporting therapeutic and cellular collection procedures. Miltenyi Biotec provides integrated cell processing technologies used across research and commercial cell therapy workflows. Fresenius Kabi and Haemonetics maintain strong positions in transfusion medicine and blood management technologies, supporting hospitals, blood centers, and cellular therapy organizations. Overall, the Leukapheresis Market is transitioning from a specialized blood treatment segment into a critical enabling technology for the expanding cell and gene therapy ecosystem. Growth opportunities are increasingly concentrated around advanced disposable systems, closed-loop processing technologies, automated cell collection platforms, and partnerships between medical device companies and biotechnology manufacturers. Cell Therapy and Specialized Separation Reshape the Growth Mix Product Type: Leukapheresis Disposables Lead Revenue Generation While Advanced Collection Systems Support Future Growth Leading Subsegment: Leukapheresis Disposables Leukapheresis disposables represent the largest revenue-generating segment of the Leukapheresis Market, accounting for 58% of global market revenue and generating USD 143.72 million in 2025. The segment is projected to expand at a CAGR of 9.33% during 2026–2032, supported by rising demand for sterile single-use collection systems in hematological disease management, CAR T-cell therapy manufacturing, and advanced cellular therapies. These disposable kits enable safe blood processing, cell separation, and efficient leukocyte collection across automated apheresis platforms. Fastest-Growing Subsegment: Advanced Cell Separation and Specialized Processing Solutions Advanced separation technologies are emerging as the fastest-growing segment within the Leukapheresis Market, generating USD 19.82 million in revenue in 2025 and accounting for an 8% market share. The segment is projected to expand at a CAGR of 10.50% from 2026 to 2032, driven by the adoption of microfluidic cell separation and immunomagnetic sorting technologies that enable higher precision, reduced extracorporeal blood volume, and improved safety compared with conventional centrifugation-based leukapheresis systems. Application: Cell Therapy Manufacturing Becomes the Strategic Growth Engine Beyond Traditional Therapeutic Use Leading Subsegment: Therapeutic Leukapheresis Therapeutic leukapheresis remains the dominant application segment in the Leukapheresis Market, contributing 55% of the total market share with revenue of USD 136.29 million in 2025. The segment is expected to expand at a CAGR of 7.61% from 2026 to 2032, supported by the growing need for rapid management of hyperleukocytosis and leukostasis in critical hematological conditions. Therapeutic leukapheresis enables the emergency removal of excess white blood cells from circulation, helping reduce blood viscosity, prevent organ complications, and provide immediate cytoreduction support before definitive treatments such as chemotherapy take effect. Fastest-Growing Subsegment: Cell Therapy Manufacturing & Research Applications Cell therapy manufacturing is emerging as the fastest-growing application segment within the Leukapheresis Market, contributing 38% of total market revenue with USD 94.16 million in 2025 and projected to expand at a CAGR of 10.50% during 2026–2032. The increasing adoption of CAR-T therapies, personalized cell-based treatments, and advanced immunotherapies is strengthening demand for leukapheresis procedures as a critical source of high-quality cellular starting material. Leukapheresis enables the collection of patient-derived immune cells required for manufacturing workflows, while therapy developers define collection specifications, cell yield requirements, processing timelines, and transportation protocols to maintain product quality. The segment’s growth is closely linked with expanding cell therapy pipelines and increasing commercial-scale manufacturing capacity. End User: Hospitals Dominate Current Demand While Biopharma Companies Create New Revenue Opportunities Leading Subsegment: Hospitals and Transplant Centers Hospitals and transplant centers represent the leading end-user segment in the Leukapheresis Market, accounting for 62% of the market share and generating USD 153.64 million in revenue in 2025. This segment is projected to expand at a CAGR of 8.26% from 2026 to 2032, supported by the growing use of leukapheresis procedures for acute leukemia management, hematopoietic stem cell collection, and advanced cellular therapy manufacturing. These facilities operate as primary leukapheresis centers by integrating specialized apheresis units, transplant programs, and multidisciplinary clinical teams. Their role extends from emergency reduction of elevated leukocyte counts in hyperleukocytosis cases to collecting CD34+ stem cells and immune cell populations used in regenerative medicine and CAR T-cell therapies. Fastest-Growing Subsegment: Biopharmaceutical Companies and CDMOs Biopharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) represent the fastest-growing end-user segment in the Leukapheresis Market, accounting for 15% of the global market share with revenue of USD 37.17 million in 2025. This segment is projected to expand at a CAGR of 11.63% during 2026–2032, driven by increasing adoption of leukapheresis-derived starting materials for CAR-T therapies, cell-based immunotherapies, and advanced gene therapy manufacturing. Biopharma companies lead therapeutic development and clinical programs, while CDMOs support GMP processing, cryopreservation, quality testing, and scalable leukapheresis workflows. Technology: Centrifugation-Based Platforms Maintain Leadership While Specialized Separation Technologies Gain Adoption Leading Subsegment: Centrifugation-Based Leukapheresis Systems Centrifugation-based systems dominate the Leukapheresis Market’s technology landscape, generating USD 193.28 million revenue in 2025 with a 78% market share and expanding at a CAGR of 8.40% during 2026–2032. These systems separate blood components through centrifugal force, enabling efficient isolation of white blood cells for therapeutic leukodepletion and cellular collection applications including CAR-T therapy and stem cell transplantation. They remain widely adopted due to their established processing efficiency and ability to handle large blood volumes in clinical leukapheresis procedures globally. Fastest-Growing Subsegment: Selective Adsorption and Advanced Separation Technologies Selective adsorption and advanced separation technologies represented 8% of the Leukapheresis Market, generating USD 19.82 million in revenue in 2025, and are projected to expand at a CAGR of 10.50% from 2026 to 2032. These technologies improve leukapheresis efficiency by enabling selective removal of targeted immune cells, including activated granulocytes, monocytes, and inflammatory mediators, while preserving other blood components compared with conventional separation approaches. Adsorptive columns such as Cellsorba and Adacolumn support immunomodulatory therapies by reducing inflammatory cell activity, while emerging microfluidic separation platforms are enhancing precision, lowering extracorporeal volume requirements, and expanding applications across complex inflammatory disorders and vulnerable patient groups. Geography: North America Leads Market Revenue While Asia-Pacific Emerges as the Expansion Hub Leading Region: North America North America remains the largest regional contributor to the Leukapheresis Market, accounting for 42% of global revenue with a market value of USD 104.08 million in 2025. The region's advanced healthcare infrastructure, growing utilization of leukapheresis procedures, and increasing demand for cellular therapy manufacturing support its leadership position. The North American leukapheresis market is projected to expand at a CAGR of 8.28% during 2026–2032, driven by rising applications in hematology, oncology, and cell-based therapies across hospitals and specialized treatment centers. Fastest-Growing Region: Asia-Pacific Asia-Pacific leukapheresis market is witnessing accelerated expansion, supported by increasing adoption of advanced cell separation technologies, rising hematological disorder burden, and growing investments in cellular therapy infrastructure. The region accounted for 24% of the global market, generating USD 59.47 million revenue in 2025, and is projected to expand at a CAGR of 10.46% during 2026–2032. Increasing availability of apheresis centers, advancements in CAR-T cell therapy programs, and improving healthcare capabilities across China, Japan, India, and South Korea are strengthening regional demand for leukapheresis products and services. Terumo BCT Sets the Pace in Automated Cell Collection Leading Company: Terumo Blood & Cell Technologies (Terumo BCT) Terumo Blood & Cell Technologies (Terumo BCT) is one of the leading companies in the global leukapheresis ecosystem, supported by its strong installed base of automated apheresis platforms, therapeutic blood processing technologies, and integration with cell and gene therapy workflows. The company’s flagship Spectra Optia™ Apheresis System is widely used for white blood cell collection, therapeutic apheresis, stem cell collection, and preparation of starting material for CAR-T and other cellular therapies. Terumo BCT states that Spectra Optia supports approximately 94% of white blood cell apheresis collections in North America and around 67% globally (excluding extracorporeal photopheresis applications), demonstrating its significant presence in clinical cell collection workflows. The company’s competitive advantage comes from its positioning across the complete cell therapy value chain, from initial leukapheresis collection to downstream cell processing. Terumo BCT serves hospitals, blood centers, therapeutic apheresis clinics, research organizations, and cell therapy developers across more than 150 countries, supported by multiple manufacturing sites and innovation centers. Its expansion into cell and gene therapy solutions has strengthened demand for its platforms, as pharmaceutical companies increasingly require standardized and scalable cell collection processes for commercial therapies. The company has also expanded clinical adoption through partnerships and healthcare programs. For example, the Spectra Optia system was selected by NHS England under the MedTech Funding Mandate to expand automated red blood cell exchange treatment for sickle cell disease, supporting wider adoption of automated apheresis technologies in advanced healthcare systems. Other Key Companies and Their Market Role Fresenius Kabi (Germany): Provides automated apheresis collection systems, including the Amicus Separator, supporting blood component collection, cell processing, and hospital-based apheresis workflows. Haemonetics Corporation (United States): Focuses on blood management and apheresis technologies through platforms such as NexSys PCS and MCS systems, supporting blood centers with automated collection efficiency and component separation solutions. Miltenyi Biotec (Germany): Specializes in cellular processing technologies, magnetic cell separation systems, and research solutions used in immune-cell isolation and cell therapy manufacturing workflows. Asahi Kasei Medical (Japan): Develops therapeutic apheresis and blood purification technologies, including membrane-based separation solutions for specialized clinical applications. Macopharma (France): Supplies blood processing products, filtration solutions, collection systems, and disposable components used in transfusion medicine and cell processing. Charles River Laboratories – HemaCare (United States): Provides human-derived biological materials, including leukopaks and immune-cell products, supporting pharmaceutical research and cell therapy development. StemExpress (United States): Supplies customized human cell products and donor-derived cellular materials used in immunotherapy research, biomarker studies, and regenerative medicine. BioIVT (United States): Provides specialized biological specimens, including peripheral blood mononuclear cells (PBMCs) and immune-cell collections for biotechnology and pharmaceutical research. SCTbio (Czech Republic): Supports cell therapy manufacturing services and specialized cellular processing capabilities for emerging biotechnology companies. Analyst View: Leukopak Quality and Automation Define the Next Phase The leukapheresis market is evolving from a specialized hematology procedure segment into a critical infrastructure component of the expanding cell and gene therapy ecosystem. The strongest growth opportunities are emerging around automated apheresis platforms, advanced disposable systems, closed-system cell collection workflows, and high-quality leukopak supply for CAR-T therapy and immunotherapy manufacturing. Increasing commercialization of cellular therapies, rising clinical trial activity, and growing demand for standardized immune-cell collection processes are reshaping market priorities. Leukapheresis Market Report Coverage at a Glance Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 247.80 Million Revenue Forecast in 2032 USD 444.63 Million Overall Growth Rate CAGR of 8.71% (2026–2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026–2032) Segmentation By Product Type, By Application, By End User, By Technology, By Geography By Product Type Leukapheresis Disposables, Leukapheresis Devices, Filtration Systems and Specialized Cell Separation Solutions By Application Therapeutic Leukapheresis, Cell Therapy Manufacturing & Research Applications, Other Therapeutic Applications By End User Hospitals and Transplant Centers, Blood Centers and Transfusion Organizations, Biopharmaceutical Companies and CDMOs, Academic and Research Institutions By Technology Centrifugation-Based Leukapheresis Systems, Membrane Filtration-Based Systems, Selective Adsorption and Advanced Separation Technologies By Geography North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers therapeutic leukapheresis for hematological emergencies and leukocyte collection for advanced cellular therapies Customization Option Available upon request Frequently Asked Question About This Report Q1: What factors are driving growth in the market? A1: Growth is supported by increasing demand for therapeutic procedures in hematological disorders and expanding use of leukocyte collection for CAR-T therapies and other cellular treatments. Rising cell therapy manufacturing activity is creating additional demand for collection systems and consumables. Q2: How is technology advancement influencing adoption in the industry? A2: Automated apheresis platforms, advanced separation technologies, and closed-system processing solutions are improving collection efficiency and supporting large-scale cell therapy workflows. These technologies help maintain consistent cell quality for therapeutic applications. Q3: Which application is expected to create major opportunities in the market? A3: Cell therapy manufacturing and research applications are creating significant opportunities due to growing CAR-T therapy adoption and increasing demand for patient-derived immune cells. This segment is projected to expand at the fastest CAGR of 10.50% during 2026–2032. Q4: Why are biopharmaceutical companies becoming important users in the industry? A4: Biopharmaceutical companies and CDMOs are increasingly using leukapheresis-derived cellular materials for CAR-T therapies, immunotherapies, and gene therapy manufacturing. Their demand is supported by expanding clinical pipelines and the need for scalable GMP processing capabilities. Q5: Which region is expected to witness the fastest expansion in the market? A5: Asia-Pacific is expected to record the fastest growth with a CAGR of 11.35% during 2026–2032. Increasing investments in cell therapy infrastructure, growing apheresis center availability, and rising adoption of advanced healthcare technologies are supporting regional expansion. Sources: Government, Regulatory & Clinical Sources National Cancer Institute (NCI) – Acute Myeloid Leukemia (AML) Overview https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq American Cancer Society – Leukemia Statistics and Incidence https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/key-statistics.html National Marrow Donor Program (NMDP) – Hematopoietic Cell Transplantation Information https://www.nmdp.org/ Center for International Blood and Marrow Transplant Research (CIBMTR) – Transplant Activity Reports https://cibmtr.org/ U.S. FDA – Approved Cellular and Gene Therapy Products (CAR-T Therapies) https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products U.S. FDA – Approved CAR-T Cell Therapies Database https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/products-approved-cellular-and-gene-therapy-products ClinicalTrials.gov – CAR-T Cell Therapy Clinical Trials Database https://clinicaltrials.gov/ National Institutes of Health (NIH) – Cell and Gene Therapy Research https://www.nih.gov/ PubMed – Leukapheresis in Acute Leukemia and Hyperleukocytosis Management https://pubmed.ncbi.nlm.nih.gov/ PubMed – Leukapheresis as Starting Material Collection for CAR-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/ Company Sources Terumo Blood and Cell Technologies – Spectra Optia Apheresis System https://www.terumobct.com/products-and-services/spectra-optia Terumo Blood and Cell Technologies – Cell and Gene Therapy Solutions https://www.terumobct.com/cell-and-gene-therapy Terumo Blood and Cell Technologies – Company Overview https://www.terumobct.com/about-us Fresenius Kabi – Amicus Separator System https://www.fresenius-kabi.com/us/products/transfusion-technology/amicus-separator Haemonetics – Apheresis and Blood Management Solutions https://www.haemonetics.com/products Miltenyi Biotec – CliniMACS Cell Therapy Platform https://www.miltenyibiotec.com/ Miltenyi Biotec – Cell Processing and Magnetic Separation Technologies https://www.miltenyibiotec.com/US-en/products-and-services/clinical-applications/cell-therapy.html Asahi Kasei Medical – Therapeutic Apheresis Systems https://www.asahi-kasei.co.jp/medical/en/ Macopharma – Blood Processing Solutions https://www.macopharma.com/ Charles River Laboratories – HemaCare Cell Products https://www.criver.com/products-services/cell-and-gene-therapy/hema-care BioIVT – Human Biological Specimens and Leukopak Products https://www.bioivt.com/ StemExpress – Cellular Therapy Research Solutions https://www.stemexpress.com/ SCTbio – Cell Therapy Manufacturing Services https://www.sctbio.com/ Table of Contents - Global Leukapheresis Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Application, End User, Technology, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Application, End User, Technology, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Application, End User, and Technology Investment Opportunities in the Leukapheresis Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Leukapheresis Disposables, Automated Collection Platforms, Cell Therapy Manufacturing, Closed-System Processing, and Advanced Cell Separation Solutions Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Leukapheresis in Therapeutic Hematology, Cell Therapy Manufacturing, and Hematopoietic Stem Cell Collection Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Clinical Workflow Factors Role of Therapeutic Leukapheresis, Cell Therapy Manufacturing, Hematopoietic Stem Cell Collection, and Advanced Cellular Processing in Market Expansion Automation, Closed-System Processing, Leukopak Quality, Disposable Collection Systems, and Advanced Cell Separation Trends Global Leukapheresis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Leukapheresis Disposables Leukapheresis Devices Filtration Systems and Specialized Cell Separation Solutions Market Analysis by Application: Therapeutic Leukapheresis Cell Therapy Manufacturing & Research Applications Other Therapeutic Applications Market Analysis by End User: Hospitals and Transplant Centers Blood Centers and Transfusion Organizations Biopharmaceutical Companies and CDMOs Academic and Research Institutions Market Analysis by Technology: Centrifugation-Based Leukapheresis Systems Membrane Filtration-Based Systems Selective Adsorption and Advanced Separation Technologies Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Leukapheresis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, End User, and Technology Country-Level Breakdown: United States Canada Mexico Europe Leukapheresis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, End User, and Technology Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Leukapheresis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, End User, and Technology Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Leukapheresis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, End User, and Technology Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Leukapheresis Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Application, End User, and Technology Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Terumo Blood and Cell Technologies Fresenius Kabi Haemonetics Corporation Miltenyi Biotec Asahi Kasei Medical Macopharma Charles River Laboratories – HemaCare StemExpress BioIVT SCTbio Fenwal Grifols Immucor Danaher Competitive Landscape and Strategic Insights Benchmarking Based on Automated Apheresis Platforms, Disposable Collection Systems, Cell Processing Integration, Clinical Adoption, Distribution Network, and Regional Presence Supplier Qualification and Compliance Capability Analysis Leukapheresis Disposable and Collection System Positioning Therapeutic Leukapheresis and Advanced Cellular Therapy Competitiveness Cell Therapy Manufacturing, Leukopak Collection, and Closed-System Processing Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Application, End User, Technology, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Regulatory Compliance and Clinical Workflow Risk Analysis Technology Adoption Trends Across Centrifugation-Based Leukapheresis Systems, Membrane Filtration-Based Systems, Selective Adsorption, and Advanced Separation Technologies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Application, End User, and Technology (2025 vs. 2032) Global Leukapheresis Ecosystem and Value Chain Analysis